ABVC - ABVC BioPharma enters into $3M clinical services contract with NeuCen BioMed

ABVC Biopharma (NASDAQ:ABVC) has announced that BioKey, a wholly-owned subsidiary of the Co., has entered into a $3M clinical services contract with NeuCen BioMed. The contract will guide two NeuCen drug products, CEN501 and NEU001, through completion of Phase II clinical studies under U.S. FDA IND regulatory requirements. Under the terms, BioKey will receive payments totaling $3M over a 3-year period with each payment amount to be determined by certain regulatory milestones obtained in connection with CEN501. “We expect this contract, together with the recently executed agreement with Define BioTech to purchase $800,000 of our maitake dietary supplement over the next year, will allow BioKey to achieve financial profitability earlier in 2022 than anticipated.” said Dr. Howard Doong, CEO of ABVC BioPharma.

For further details see:

ABVC BioPharma enters into $3M clinical services contract with NeuCen BioMed